Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Body Composition Sub-study of the D2EFT Trial

Trial Profile

Body Composition Sub-study of the D2EFT Trial

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Darunavir (Primary) ; Dolutegravir (Primary) ; Emtricitabine (Primary) ; Lamivudine (Primary) ; Ritonavir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Nucleotide reverse transcriptase inhibitors
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Feb 2019 Planned initiation date changed from 15 Jan 2019 to 15 Apr 2019.
    • 27 Nov 2018 Planned End Date changed from 15 Nov 2021 to 15 Jan 2022.
    • 27 Nov 2018 Planned primary completion date changed from 15 Nov 2021 to 15 Jan 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top